Banque Cantonale Vaudoise Invests $88,000 in Evolent Health, Inc. (NYSE:EVH)

Banque Cantonale Vaudoise acquired a new position in shares of Evolent Health, Inc. (NYSE:EVH) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,676 shares of the technology company’s stock, valued at approximately $88,000.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Evolent Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 10,821,331 shares of the technology company’s stock valued at $357,429,000 after buying an additional 226,691 shares during the last quarter. Wellington Management Group LLP grew its stake in Evolent Health by 96.1% in the 4th quarter. Wellington Management Group LLP now owns 8,313,157 shares of the technology company’s stock valued at $274,584,000 after buying an additional 4,073,959 shares during the last quarter. Rock Springs Capital Management LP grew its stake in Evolent Health by 1.6% in the 3rd quarter. Rock Springs Capital Management LP now owns 3,865,000 shares of the technology company’s stock valued at $105,244,000 after buying an additional 61,500 shares during the last quarter. RA Capital Management L.P. acquired a new position in Evolent Health in the 3rd quarter valued at about $74,520,000. Finally, Point72 Asset Management L.P. grew its stake in Evolent Health by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,675,000 shares of the technology company’s stock valued at $88,355,000 after buying an additional 1,199,400 shares during the last quarter.

Evolent Health Price Performance

Shares of NYSE:EVH opened at $22.03 on Tuesday. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -17.62 and a beta of 1.44. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.02 and a quick ratio of 1.02. The firm has a 50 day simple moving average of $24.75 and a 200 day simple moving average of $29.19. Evolent Health, Inc. has a one year low of $20.54 and a one year high of $35.00.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, May 9th. The technology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.04. Evolent Health had a negative net margin of 5.07% and a positive return on equity of 6.90%. The firm had revenue of $639.65 million during the quarter, compared to analysts’ expectations of $601.60 million. Research analysts predict that Evolent Health, Inc. will post 0.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on EVH shares. JMP Securities cut their price objective on shares of Evolent Health from $38.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. JPMorgan Chase & Co. cut their price objective on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. Citigroup started coverage on shares of Evolent Health in a report on Monday, April 22nd. They issued a “buy” rating and a $40.00 price objective for the company. Canaccord Genuity Group cut their price objective on shares of Evolent Health from $44.00 to $41.00 and set a “buy” rating for the company in a report on Friday, May 10th. Finally, Oppenheimer started coverage on shares of Evolent Health in a report on Friday, March 1st. They issued an “outperform” rating and a $45.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Evolent Health has an average rating of “Moderate Buy” and a consensus price target of $42.00.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.